Company Description
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.
Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Thomas Fitzgerald |
Contact Details
Address: 6 Liberty Square, Suite 2382 Boston, Massachusetts 02109 United States | |
| Phone | 857 837 3099 |
| Website | transcodetherapeutics.com |
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001829635 |
| CUSIP Number | 89357L105 |
| ISIN Number | US89357L3033 |
| Employer ID | 81-1065054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. Fitzgerald M.B.A. | Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration and Director |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Executive Chairman of the Board |
| Dr. Zdravka Medarova Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor and Member of Scientific Advisory Board |
| Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 17, 2024 | EFFECT | Notice of Effectiveness |
| Dec 12, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 6, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |